BRCA1 and mantle cell lymphoma: Olaparib has been shown to sensitize cells to these treatments in cells that have deficiencies in some DNA repair mechanisms and, for this reason, it has been used in breast and ovarian cancer with BRCA1 mutations [17, 18], or in mantle cell lymphomas with alterations of the ATM pathway [15].